1-methyl-3-isobutylxanthine has been researched along with Autosomal Dominant Juvenile Parkinson Disease in 1 studies
1-Methyl-3-isobutylxanthine: A potent cyclic nucleotide phosphodiesterase inhibitor; due to this action, the compound increases cyclic AMP and cyclic GMP in tissue and thereby activates CYCLIC NUCLEOTIDE-REGULATED PROTEIN KINASES
3-isobutyl-1-methylxanthine : An oxopurine that is xanthine which is substituted at positions 1 and 3 by methyl and isobutyl groups, respectively.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rangel-Barajas, C | 1 |
| Silva, I | 1 |
| García-Ramírez, M | 1 |
| Sánchez-Lemus, E | 1 |
| Floran, L | 1 |
| Aceves, J | 1 |
| Erlij, D | 1 |
| Florán, B | 1 |
1 other study available for 1-methyl-3-isobutylxanthine and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
6-OHDA-induced hemiparkinsonism and chronic L-DOPA treatment increase dopamine D1-stimulated [(3)H]-GABA release and [(3)H]-cAMP production in substantia nigra pars reticulata of the rat.
Topics: 1-Methyl-3-isobutylxanthine; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; | 2008 |